Global Journal of Medical and Pharmaceutical Sciences
eISSN: 2957-3629 pISSN: 2957-3610

VOLUME03 ISSUE10
Published 01-10-2024 *Page No. 1-5*

A RARE CASE OF ISCHEMIC PRIAPISM FOLLOWING ALPHA BLOCKER THERAPY

Dr. Vivek Priyadarshi

MS, Department of Urology, IPGMER and SSKM Hospital, Kolkata-20, India

ABSTRACT

Ischemic priapism is a prolonged, painful erection that can lead to significant morbidity if not promptly treated. While various etiologies have been identified, the occurrence of ischemic priapism as a result of alpha blocker therapy is exceedingly rare. This report presents the case of a 45-year-old male with a history of benign prostatic hyperplasia who developed ischemic priapism following the initiation of alpha blocker medication. The patient experienced an erection lasting over four hours, accompanied by severe pain and discomfort. Upon presentation to the emergency department, a thorough evaluation confirmed the diagnosis of ischemic priapism, and the patient was promptly treated with aspiration and irrigation of the corpus cavernosum. Follow-up assessments revealed a successful resolution of symptoms and restoration of erectile function.

This case highlights the importance of recognizing alpha blockers as a potential cause of ischemic priapism, even in the absence of prior reports linking the two. It underscores the necessity for healthcare providers to be vigilant in monitoring patients receiving alpha blocker therapy for signs of priapism. Furthermore, this case adds to the limited literature on drug-induced ischemic priapism and emphasizes the need for further investigation into the underlying mechanisms and management strategies associated with this rare condition.

KEYWORDS

Ischemic priapism, alpha blockers, benign prostatic hyperplasia, prolonged erection, case report, erectile dysfunction, pharmacological adverse effects, emergency treatment, penile aspiration, urology.

INTRODUCTION

Ischemic priapism is a urological emergency characterized by a prolonged and painful erection that lasts more than four hours, unassociated with sexual arousal or stimulation. It results from impaired venous outflow from the penis, leading to a trapped blood state within the corpus cavernosum. This condition can result in irreversible penile damage, erectile dysfunction, and significant morbidity if not addressed promptly. Although priapism can occur due to various causes, including hematological disorders, medications, and trauma, the occurrence of ischemic priapism specifically associated with alpha blocker therapy is exceedingly rare. Alpha blockers, commonly prescribed for conditions such as benign prostatic hyperplasia (BPH) and hypertension, work by antagonizing adrenergic receptors, leading to smooth muscle relaxation in the prostate and bladder

neck. However, these medications can also influence vascular dynamics, potentially precipitating priapism in susceptible individuals.

This report presents a unique case of ischemic priapism that developed in a 45-year-old male patient following the initiation of alpha blocker therapy for BPH. The rarity of this occurrence necessitates a detailed examination of the clinical presentation, treatment options, and potential mechanisms linking alpha blockers to ischemic priapism. Recognizing the signs and symptoms of ischemic priapism early is crucial for effective management, as delays in treatment can result in irreversible damage. This case aims to enhance awareness among healthcare professionals about the potential adverse effects of alpha blockers, contribute to the existing body of literature, and underscore the importance of monitoring patients for signs of priapism during alpha blocker therapy. Additionally, it highlights the need for further research into the pharmacological mechanisms that may predispose certain individuals to this rare but serious complication.

METHOD

This case report describes the evaluation and management of a 45-year-old male patient who presented to the emergency department with a prolonged erection lasting more than four hours, characterized by significant pain and discomfort. The patient had a medical history notable for benign prostatic hyperplasia (BPH), for which he had recently commenced therapy with an alpha blocker, specifically tamsulosin, approximately three weeks prior to presentation. The decision to initiate tamsulosin was made based on the patient's increasing urinary symptoms, which included nocturia, urgency, and difficulty in urination.

Upon presentation, the patient was triaged by the emergency department staff and underwent an initial assessment that included a comprehensive medical history and physical examination. The medical history was meticulously reviewed to identify potential contributing factors to the episode of priapism, including any recent trauma, hematological disorders, or the use of other medications. The patient denied any history of similar episodes, significant trauma to the genital area, or any hematological conditions such as sickle cell disease or thrombophilia. However, he acknowledged the recent initiation of tamsulosin as part of his treatment regimen.

Physical examination revealed a markedly engorged penis with a rigid shaft but soft glans, consistent with ischemic priapism. There was significant tenderness upon palpation. No lesions or deformities were noted. The patient's vital signs were stable, and a digital rectal examination indicated an enlarged prostate consistent with BPH. Blood tests were performed to evaluate the complete blood count, liver function tests, and renal function, while a coagulation profile was also obtained to rule out any underlying coagulopathy.

In alignment with established clinical protocols, the patient was diagnosed with ischemic priapism based on the clinical findings and the duration of the erection. The treatment plan included immediate intervention to relieve the priapism and restore normal penile function. The patient was taken to the urology department, where he underwent penile aspiration therapy. This procedure involved the use of a 21-gauge needle to aspirate the trapped blood from the corpus cavernosum, performed under local anesthesia to minimize discomfort. Approximately 30 mL of dark, viscous blood was aspirated, indicating significant stasis. After aspiration, normal saline irrigation was performed to flush the corpus cavernosum and enhance blood flow.

Post-procedure, the patient was monitored closely in a recovery area for any immediate complications, and follow-up assessments were conducted to evaluate the efficacy of the intervention. Pain scores were assessed using a visual analog scale to ensure that the patient's discomfort was adequately managed. The patient reported a gradual decrease in pain and a return of erectile function within 24 hours following the procedure. He was discharged with instructions for follow-up care and recommendations for avoiding medications associated with priapism, including continued caution regarding the use of alpha blockers.

In addition to the clinical management, a thorough literature review was conducted to understand the relationship between alpha blocker therapy and the occurrence of ischemic priapism. The review included searching databases such as PubMed, Scopus, and Google Scholar using keywords like "ischemic priapism," "alpha blockers," "tamsulosin," and "case report." Relevant studies, case reports, and reviews published within the last two decades were included to identify any documented cases or potential mechanisms linking these medications to priapism.

This methodological approach aims to provide comprehensive insights into the case while contributing to the growing body of knowledge regarding the side effects of alpha blockers. By documenting this rare occurrence, the report seeks to inform healthcare professionals about the need for awareness and prompt intervention in similar clinical scenarios.

RESULTS

The patient presented with ischemic priapism, characterized by a painful erection lasting over four hours, which began shortly after the initiation of tamsulosin therapy for benign prostatic hyperplasia. Upon examination, the patient exhibited a rigid penile shaft with tenderness but a soft glans, consistent with ischemic priapism. Laboratory investigations revealed a normal complete blood count, renal function tests, and coagulation profile, ruling out underlying hematological disorders or coagulopathies.

Following the diagnosis, the patient underwent penile aspiration therapy, during which approximately 30 mL of dark, thick blood was successfully evacuated from the corpus cavernosum. Post-aspiration, the patient reported a significant reduction in pain and a return of erectile function within 24 hours, with no immediate complications observed. He was closely monitored in the recovery area, where vital signs remained stable throughout the observation period.

A follow-up assessment conducted one week post-discharge revealed that the patient experienced no recurrence of priapism, and he reported satisfactory erectile function. The case was discussed during a departmental meeting, leading to a broader discussion on the potential association between alpha blocker therapy and the incidence of ischemic priapism, which is seldom reported in the literature.

The literature review revealed a limited number of documented cases linking alpha blockers to priapism, primarily focusing on the pharmacological effects of these medications on penile vascular dynamics. Most reported cases emphasized the need for awareness among healthcare providers regarding this rare but serious complication.

The overall findings underscore the necessity for vigilance in monitoring patients prescribed alpha blockers, particularly those with additional risk factors for priapism. This case contributes to the existing body of literature by documenting a rare instance of ischemic priapism following alpha blocker therapy, emphasizing the importance of prompt recognition and intervention in preventing long-term complications associated with prolonged erection.

DISCUSSION

This case of ischemic priapism following alpha blocker therapy highlights a significant and uncommon adverse effect that healthcare providers should be aware of, especially in patients being treated for benign prostatic hyperplasia (BPH). Although priapism is more commonly associated with hematological disorders and other pharmacological agents, the occurrence of ischemic priapism due to alpha blockers is infrequently documented, making this case noteworthy. The mechanism underlying this association may involve the alteration of vascular tone and blood flow dynamics due to the pharmacological action of alpha blockers, which lead to smooth muscle

relaxation in the prostate and bladder neck but may inadvertently affect penile vascular physiology.

The patient's presentation aligns with the classic definition of ischemic priapism, characterized by a prolonged erection lasting over four hours and associated with significant pain. The initial management through penile aspiration proved effective, alleviating the condition and restoring erectile function. This outcome underscores the critical importance of prompt intervention in managing ischemic priapism to prevent long-term complications such as penile fibrosis and erectile dysfunction.

In reviewing the literature, it is evident that while the incidence of priapism associated with alpha blockers is low, it is essential for clinicians to maintain a high index of suspicion, particularly in patients with risk factors such as a history of priapism or concurrent use of other medications known to induce priapism. The rarity of such cases in the literature does not negate the potential for this complication to arise, highlighting a gap in the current understanding and reporting of drug-related adverse effects.

Furthermore, this case emphasizes the need for comprehensive patient education regarding the potential side effects of medications. Clinicians should inform patients about the signs and symptoms of priapism and advise them to seek immediate medical attention if such symptoms arise. This proactive approach can facilitate timely management and mitigate the risks associated with prolonged episodes of priapism.

This rare case serves as a reminder of the complexities of pharmacotherapy in managing BPH and the importance of vigilant monitoring for adverse effects. As the medical community continues to advance in understanding medication-related complications, further research is warranted to explore the pharmacological mechanisms by which alpha blockers can lead to ischemic priapism. Sharing such case reports can enhance clinical awareness and contribute to the establishment of guidelines for the management of priapism in patients undergoing treatment with alpha blockers.

CONCLUSION

In summary, this case report underscores the importance of recognizing ischemic priapism as a rare but potentially serious complication associated with alpha blocker therapy. The patient presented with a prolonged and painful erection following the initiation of tamsulosin for benign prostatic hyperplasia, which was successfully managed through prompt penile aspiration. This incident highlights the need for heightened awareness among healthcare providers regarding the risk factors and clinical manifestations of priapism in patients receiving alpha blockers.

Given the limited documentation of such cases in the existing literature, this report serves to contribute valuable insights into the relationship between pharmacological treatment and the incidence of priapism. It emphasizes the necessity for patient education about the potential side effects of medications and the importance of immediate medical intervention when symptoms arise.

Future studies should explore the underlying mechanisms connecting alpha blocker therapy to ischemic priapism, along with establishing guidelines for monitoring and managing this rare condition. As the landscape of medication use in managing urological conditions evolves, continued vigilance and education will be paramount in preventing adverse outcomes and ensuring patient safety.

REFERENCES

1. Pryor CAMPBELL-WALSH UROLOGY. 10th ed. Philedelphia(U.S.A): elsevier saunders. 2011. p763
2. Broderick G A. “Priapism” In:CAMPBELL-WALSH UROLOGY. 10th ed. Philedelphia(U.S.A): elsevier saunders. 2011. p749-769.

3. Nejad H S, Jackson I. New-Onset Priapism Associated with Ingestion of Terazosin in an Otherwise Healthy Man. The Journal of Sexual Medicine. 2007 Nov; 4 (6): 1766-68.

4. Kilinc M, Piskin M, Guven S, Gurbuz R, Odev K, Kaynar M. Partial priapism secondary to tamsulosin: acasereport and review of the literature Andrologia. 2009 June; 41(3):199-201.

5. Venyo A. Tamsulosin-induced-priapism: A Rare Complication Associated with the Management of Ureteric Colic. Webmed Central Urology. 2010 Dec; 1(12): WMC001295

6. Pahuja A, Bashir J, Williamson E M and Barber N. Unresolved priapism secondary to tamsulosin. International Journal of Impotence Research: 293-94